**Bausch Health Companies Inc. Reports Fiscal Year 2025 Results**

Bausch Health Companies Inc. (NYSE: BHC) announced its financial results for the fiscal year ended December 31, 2025, reporting total revenues of $10.27 billion, an increase of $641 million or 7% compared to $9.63 billion in 2024. The revenue growth was primarily driven by improved net realized pricing, higher volumes, favorable foreign currency impacts, the impact of divestitures and discontinuations, and incremental sales from acquisitions. Operating income for the year was $1.81 billion, up from $1.55 billion in the previous year. Net income attributable to Bausch Health Companies Inc. was $157 million, a significant improvement from a net loss of $46 million in 2024. Basic and diluted earnings per share attributable to Bausch Health Companies Inc. were both $0.42, compared to a loss of $0.13 per share in the prior year.

The company's five reportable segments contributed to the overall performance. The Salix segment reported revenues of $2.58 billion, up 11% year-over-year, while the International segment saw a 2% increase to $1.13 billion. Solta Medical experienced substantial growth, with revenues increasing by 18% to $518 million. The Diversified segment's revenue slightly decreased by 1% to $937 million, and Bausch + Lomb's revenue increased by 6% to $5.10 billion. The company's strategic focus on core therapeutic areas and geographies, along with effective capital allocation, contributed to these results.

Key strategic developments during the year included the acquisition of DURECT Corporation, a biopharmaceutical firm specializing in epigenetic therapies, and Wuhan Shibo Zhenmei Technology Co., Ltd., the aesthetics distribution business of its full-service distributor in China. These acquisitions are expected to enhance the company's product pipeline and market presence. Bausch + Lomb also completed several acquisitions, including Whitecap Biosciences, LLC, Elios Vision, Inc., and Trukera Medical, expanding its portfolio in eye health. The company continued to advance its research and development programs, with approximately 80 projects in the pipeline as of December 31, 2025.

As of December 31, 2025, Bausch Health had approximately 20,300 employees, including approximately 13,000 Bausch + Lomb employees. The company remains focused on managing its capital structure, with maturities and mandatory payments of principal balances of debt obligations totaling $20.23 billion. The company is also subject to ongoing legal proceedings, including intellectual property litigation and antitrust claims, which could have a material impact on its financial results. The company is also navigating the complexities of the Inflation Reduction Act (IRA), including the selection of Xifaxan® for drug price negotiations, and is working to mitigate its impact.

About Bausch Health Companies Inc.

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical device company focused on gastroenterology, hepatology, neurology, dermatology, and eye health through its majority-owned Bausch + Lomb subsidiary. It develops, manufactures, and markets branded, generic, and OTC pharmaceuticals, aesthetic medical devices, and eye care products across approximately 90 countries. The company leverages a diversified portfolio, extensive R&D, and a broad commercial footprint targeting healthcare providers, patients, and consumers worldwide.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.